Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 December 2023 | Story Anthony Mthembu | Photo Siyabonga Mazibuko and Anthony Mthembu
Sharon Pinky Kekana
Sharon Pinky Kekana: Deputy Minister in the Presidency for Planning, Monitoring and Evaluation.

The Gender Equality and Anti-Discrimination Office (GEADO) at the University of the Free State (UFS), in collaboration with the Central University of Technology (CUT), recently concluded its fourth bi-annual Gender Practitioners Community of Practice (CoP) conference in Clarens. The event, held from 28 to 30 November 2023, drew participation from gender practitioners representing all 26 Universities across the country. Distinguished guest speaker, Sharon Pinky Kekana, Deputy Minister in the Presidency for Planning, Monitoring and Evaluation, added valuable insights to the discussions.

Tumelo Rasebopye, Chairperson of the Gender Practitioners Community of Practice (CoP), outlined the conference’s key objectives, emphasising the need for thorough and robust engagement on issues raised in previous gatherings and the provision of essential tools for practitioners to implement upon their return to their institutions. Rasebopye stressed, ‘Part of the conference is to ensure that we engage in developing a common understanding and act at a baseline level to address the dynamics in our institutions.’’

The themes explored throughout the Conference

The conference delved into various themes through panel discussions and guest speaker sessions, covering topics such as masculinity, culture, and consent. However, the primary focus was on Gender-Based Violence and Femicide (GBVF), particularly pertinent during the 16 Days of Activism for No Violence against Women and Children.’ Kekana, in her address, considered the conference theme, ‘Accelerating actions to end gender-based violence & femicide: leaving no one behind,’ as a call to action. She urged attendees to continue to raise awareness about the devastating impact of GBVF on women, children and the nation as a whole, citing alarming statistics of 969 women murdered in the first three months of the year. 

Advocate Brenda Madumise, Co-Founder of the Wise Collective, highlighted flaws in the national justice system, pointing to prolonged sexual assault cases and the trauma inflicted on survivors during the waiting period.

Resolutions

Reflecting on the conference, Kekana deemed the discussions as an eye-opener, stressing an integrated approach involving various societal entities, including the church and religious leaders. The gender practitioners pledged to collaborate with groups such as the Student Representative Council (SRC) within their institutions to foster inclusivity.  Rasebopye affirmed, ‘’Our existence is fundamental towards the transformation of higher education, and these conferences will inform the necessary actions towards that course.’’

The GEADO, in partnership with CUT, continues to champion gender equality through informed and actionable discussions. The conference not only raised awareness about GBVF but also galvanized gender practitioners to play an active role in fostering inclusive environments within higher education institutions.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept